The pharmaceutical world is observing a major shift in blood sugar treatment with the introduction of GLP-1 transdermal devices. These systems offer a seemingly more user-friendly alternative to injections of GLP-1 drugs, minimizing the frequency of daily needle pricks. The approach releases the